



**MuTaLig COST ACTION CA15135**  
**4<sup>th</sup> WG meeting 2020 Izmir (Turkey)**  
**March, 5-6<sup>th</sup> 2020**



## **4<sup>th</sup> WG meeting – MuTaLig COST Action**

**Faculty of Pharmacy, Ege University, March 5-6<sup>th</sup> 2020**

### **Final status of WG activities within the MuTaLig COST Action**



#### **Final program**

**Thursday March 5<sup>th</sup> 2020**

8.30 Registration

9.00 **Introduction to the MuTaLig COST Action 4<sup>th</sup> WG meeting**

**Necdet BUDAK** (Rector) – Ege University (Turkey)

**Ayfer YALÇIN** (Dean of Faculty of Pharmacy) – Ege University (Turkey)

**Stefano ALCARO** (CA15135 Chair) - Università “Magna Græcia” di Catanzaro (Italy)

**Günay YETİK-ANACAK** (MC member Turkey and local organizer) – Ege University (Turkey)

***Body percussion dance show with mortar and pestle***  
***“A multi-targeting pharmacist: Galen from Aegean land”***

#### **Reports of the WG leaders**

**Moderator: Fernanda BORGES – (Vice-Chair and MC member Portugal) University of Porto (Portugal)**

**Danijel KIKELJ** – (WG1 leader) University of Ljubljana (Slovenia)

**Eugenio GAUDIO** – (WG2 leader) Oncology Research Institute, Bellinzona (Switzerland)

**Sharon BRYANT** – (WG3 leader) Inte:Ligand GmbH, Vienna (Austria)

**Hanoch SENDEROWITZ** – (WG4 leader) Bar-Ilan University, Ramat-Gan (Israel)

10.30 *Coffee break*

#### **Session I “Multi-targeting agents against cancer and infections”**

**Moderator: David C. MAGRI – (MC member Malta) University of Malta (Malta)**

11.00 **OC1 Toward Multitarget DNA Gyrase Inhibitors Possessing Antibacterial Activity**

**Danijel KIKELJ** – (WG1 leader) University of Ljubljana (Slovenia)

11.15 **OC2 Repositioning of [1,6] Naphthyridines as Antiviral Agents on HSV-1**

**Alessandra MONTALBANO** – University of Palermo (Italy)

11.30 **OC3 Indolocarbazole maleimides with dual inhibition of kinases and topoisomerase I**

**Florence MCCARTHY** – (MC member Ireland) University College, Cork (Ireland)

- 11.45 **OC4 Epigenetic Multitargeting in Cancer: Design, Synthesis And Biological Evaluation of Novel Inhibitors**  
**Filipa RAMÍLO GOMES** – University of Lisbon, Lisbon (Portugal)
- 12.00 **OC5 The effect of New Synthesized Resveratrol Derivate H1 on angiogenesis**  
**Emine Nur ÖZBEK** – Ege University, İzmir (Turkey)
- 12.15 **OC6 A Comparative Study of The Antiangiogenic Activity of Hydroxytyrosyl Alkyl Ethers as Multitargeted Bioactive Compounds**  
**Miguel Ángel MEDINA** – University of Málaga, Málaga (Spain)
- 12.30 **OC7 High throughput in-vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thymomimetics**  
**Sheraz GUL** – (MC substitute Germany) Fraunhofer Institute, Hamburg (Germany)
- 12.45 **OC8 Cytotoxic Effect of Zn(II)/Au(I), Zn(II)/Ag(I) And Ru(III) Complexes with Schiff Bases in Human Osteosarcoma Cellline**  
**Radostina ALEXANDROVA** – (MC member Bulgaria) Bulgarian Academy of Sciences (Bulgaria)
- 13.00 **OC9 Multitarget Covalent Inhibitory Property of Klavuzons**  
**Ali ÇAĞIR** – Izmir Institute of Technology (IYTE), İzmir (Turkey)
- 13.15 *Lunch and poster session*

### Session II “Multi-targeting agents against neurodegenerations”

**Moderator: Fernanda BORGES – (Vice-Chair and MC member Portugal) University of Porto (Portugal)**

- 14.45 **OC10 Expanding the medicinal chemistry Multi-Target Directed Ligands toolbox for neurodegeneration: rationally designed fragment, hybrids and conjugate small molecules**  
**Maria Laura BOLOGNESI** – (STSM coordinator) University of Bologna (Italy)
- 15.00 **OC11 Natural Product Hybrids are Potent Neuroprotectants in Vitro And in Vivo: Multi-Target Ligands with Unknown Targets?**  
**Michael DECKER** – University of Würzburg (Germany)
- 15.15 **OC12 Targeting Alzheimer’s Disease with 4-Aminochromane Derivatives**  
**Anthony BURKE** – University Evora (Portugal)
- 15:30 **OC13 Combination of Adenosine Antagonism with Additional H3R Antagonism for the Treatment of Parkinson’s Disease**  
**Holger STARK** – (MC member Germany) Heinrich Heine University of Duesseldorf (Germany)
- 15.45 **OC14 Histamine H3 receptor antagonism as a valuable component for multitarget directed ligands (MTDL)**  
**Wiesława Agnieszka FOGEL** – (MC member Poland) Medical University of Lodz (Poland)
- 16.00 **OC15 Repurposing Compounds Designed to Treat Mental Diseases as Potential Drugs Against Neurodegenerative Diseases**  
**Agnieszka A. KACZOR** – Medical University of Lublin (Poland)
- 16.15 **OC16 Mapping the chromone-3- phenylcarboxamides pharmacophore: structure-activity-toxicity and efflux transport studies**  
**Francesco Mesiti** – Università “Magna Græcia” di Catanzaro (Italy)
- 16:30 *Coffee break*

### Session III “Multi-targeting agents against vascular diseases or oxidative stress”

**Moderator: Florence MCCARTHY – (MC member Ireland) University College, Cork (Ireland)**

- 16.45 **OC17 Interplay between superoxide dismutase, catalase and peroxidase activities for salen-manganese complexes**  
**Marcelino MANEIRO** – University of Santiago de Compostela, Santiago de Compostela (Spain)
- 17.00 **OC18 Mitochondriotropic Cinnamic Acid Antioxidant Improves Cellular Resistance to Stress**  
**Ricardo AMORIM** – University of Porto, Porto (Portugal)
- 17.15 **OC19 Vascular effects of pioglitazone related to perivascular adipose tissue (PVAT)**  
**Deniz KALELİ DURMAN** – Istanbul University, İstanbul (Turkey)
- 17.30 **OC20 The journey from ethnobotanical studies to pharmacological target: The effect of imperatorin and isoimperatorin on penile relaxation**  
**Nazlıcan BELEN** – Ege University, Izmir (Turkey)
- 17.45 **OC21 A Potential Repositioning of Trimetazidine for the Treatment of Bladder Dysfunction: Effects on Mouse Detrusor Contractility and Cytoprotection**  
**Yeşim KAYA YAŞAR** – Karadeniz Technical University, Trabzon (Turkey)
- 18.15 *Transfer to gala dinner (optional)*

Friday March 6<sup>th</sup> 2020

**Session IV: “New methods in Drug Discovery, in silico pharmacology and drug repurposing”**

**Moderator: Holger STARK – (MC member Germany) Heinrich Heine University of Duesseldorf (Germany)**

- 9.00 **OC22 A Lab-on-a-Molecule with an Enhanced Fluorescent Readout on Detection of Three Chemical Species**  
**David C. MAGRI** – (MC member Malta) University of Malta (Malta)
- 9.15 **OC23 New screening libraries arising from the Prestwick Chemical Drug Library**  
**Marie Louise JUNG** – Prestwick Chemical, Strasbourg (France)
- 9.30 **OC24 Lead to Target: A Computational Approach to Identify Possible Protein Targets of Molecules with Known Experimental Biological Activity**  
**Sérgio F. SOUSA** – University of Porto (Portugal)
- 9.45 **OC25 Drug design in silico: dream, (next) future or even coming reality?**  
**Diego LIBERATI** – National Research Council of Italy @ Politecnico di Milano (Italy)
- 10.00 **OC26 Computational Approaches in Multi-target Drug Discovery**  
**Rita GUEDES** – (MC member Portugal) University of Lisbon (Portugal)
- 10.15 **OC27 Multi-Target Ligand Design is Ripe for New Methods**  
**Alfonso T. GARCÍA-SOSA** – (MC member EE, communication manager) University of Tartu (Estonia)
- 10.30 **OC28 New Inhibitors of the BmrA Pump Identified Through Virtual Screening**  
**Onur SERÇİNOĞLU** – Recep Tayyip Erdogan University, Rize (Turkey)
- 10.45 *Coffee break*
- 11.00 **Round table on perspectives of the MuTaLig community**  
**Moderator: Stefano Alcaro (CA15135 Chair) - Università “Magna Græcia” di Catanzaro (Italy)**  
**Antonio LUPIA** – (FAD manager) Net4Science academic spinoff, Catanzaro (Italy)  
**Fernanda BORGES** – (Vice-Chair and MC member Portugal) University of Porto (Portugal)  
**Danijel KIKELJ** – (WG1 leader) University of Ljubljana (Slovenia)  
**Alfonso T. GARCÍA-SOSA** – (MC member EE, communication manager) University of Tartu (Estonia)  
**Maria Laura BOLOGNESI** – (STSM coordinator) University of Bologna (Italy)
- 12.15 **Concluding remarks and best poster awarding ceremony**  
**Günay YETİK-ANACAK (MC member Turkey and local organizer) – Ege University (Turkey)**
- 12.45 *Snack and farewell*

*Poster information: Panels for posters have PORTRAIT orientation. The maximum dimensions allowed are 70 cm width x 90 cm tall.*